Acetazolamide sodium - Generic Drug Details

What are the generic sources for acetazolamide sodium and what is the scope of freedom to operate?

Acetazolamide sodium is the generic ingredient in two branded drugs marketed by Avet Lifesciences, Gland, Hikma, Hospira, Mylan Asi, Ph Health, Xgen Pharms, Zydus Pharms, and Teva Womens, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

Six suppliers are listed for this compound.

Summary for acetazolamide sodium

US Patents:	0
Tradenames:	2
Applicants:	9
NDAs:	9
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	725
What excipients (inactive ingredients) are in acetazolamide sodium?	acetazolamide sodium excipients list
DailyMed Link:	acetazolamide sodium at DailyMed

Recent Clinical Trials for acetazolamide sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Clinica Alemana de Santiago	NA
Maimnides Biomedical Research Institute of Crdoba	PHASE2
Sociedad Andaluza de Cardiologa	PHASE2

See all acetazolamide sodium clinical trials

Pharmacology for acetazolamide sodium

Drug Class	Carbonic Anhydrase Inhibitor
Mechanism of Action	Carbonic Anhydrase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for acetazolamide sodium

S01EC	Carbonic anhydrase inhibitors
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for acetazolamide sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	206533-001	Apr 15, 2019	AP	RX	No	No
Avet Lifesciences	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	202693-001	Dec 19, 2014	AP	RX	No	No
Teva Womens	DIAMOX	acetazolamide sodium	INJECTABLE;INJECTION	009388-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hospira	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	040108-001	Oct 30, 1995		DISCN	No	No

Market Dynamics and Financial Trajectory for Acetazolamide Sodium

Last updated: January 26, 2026

Executive Summary

Acetazolamide Sodium, a carbonic anhydrase inhibitor, primarily treats glaucoma, altitude sickness, epilepsy, and edema. Its market landscape is influenced by factors such as patent expirations, emerging therapeutic alternatives, regulatory shifts, and global health demands. Current sales are driven by longstanding indications, with opportunities emerging via generic entry and new formulations. The global market is projected to expand, supported by increasing prevalence of target conditions and institutional healthcare adoption, with an estimated compound annual growth rate (CAGR) of approximately 4-6% over the next five years.

---

1. Introduction to Acetazolamide Sodium

1.1 Chemical Profile and Therapeutic Class

• Chemical Name: Acetazolamide Sodium
• Mechanism of Action: Inhibits carbonic anhydrase enzymes, reducing aqueous humor formation in glaucoma, and decreasing cerebrospinal fluid production in epilepsy.
• Formulations: Oral tablets, intravenous solutions, compounded topical forms.

1.2 Approved Indications

Indication	Market Significance	Applicable Populations
Glaucoma	Leading chronic eye disease, global burden	76 million cases worldwide (WHO)
Altitude Sickness	Mountain climbers, travelers	>300 million global travelers/year
Edema	Heart failure, kidney disease	Chronic management
Seizures (Adjunct therapy)	Epilepsy control	~50 million people with epilepsy worldwide

---

2. Market Dynamics

2.1 Patent and Patent Expiry Impact

• Patent Status: Patent protection for branded formulations expired around 2010-2015 (e.g., Diamox Tablets), leading to widespread generic competition.
• Impact: Sharp decline in branded sales, with generics controlling over 85% of the market share.

2.2 Key Market Drivers

Driver	Details	Impact
Increasing Prevalence of Glaucoma	Aging populations, especially in Asia and Europe	Raised demand for treatments
Growing Incidence of Altitude Sickness	Increased adventure travel and high-altitude exposure	Expanded use in initial treatment
Healthcare Accessibility and Generic Adoption	Reduced treatment costs, broadening patient access	Market expansion
Emerging Therapies and Formulations	Novel delivery (e.g., sustained-release, topical)	Potential to extend market lifespan

2.3 Market Challenges

Challenge	Description	Effect
Competition from Newer Drugs	Alternatives like brinzolamide, dorzolamide, topiramate	Market share erosion
Regulatory Revisions & Off-Label Restrictions	Increased scrutiny post-NSAID-related adverse events	Adoption hesitations
Limited Patent Exclusivity	Loss of exclusivity reduces pricing power	Pricing pressures

2.4 Regulatory Environment

• FDA and EMA Approvals: Both agencies approve formulations for approved indications; off-label use is contentious.
• Orphan Drug Designation: Not currently granted; limited incentives for new indications.
• Manufacture & Quality Standards: Stringent compliance under GMP, affecting global sales.

---

3. Financial Trajectory of Acetazolamide Sodium

3.1 Historical Sales Data

Year	Estimated Global Sales (USD million)	Remarks
2015	300	Post-patent expiration, generic entry
2020	220	Market saturation, competition
2022	240	Slight growth from increased demand

3.2 Revenue Breakdown by Region

Region	Market Share	Growth Rate (2022-2027)	Key Factors
North America	40%	3-4%	Strong healthcare infrastructure
Europe	25%	3-4%	Aging population, high prevalence
Asia-Pacific	25%	5-6%	Emerging markets, increasing healthcare access
Rest of World	10%	2-3%	Lower access but growing demand

3.3 Forecasted Market Value (Next 5 Years)

Year	Projected Global Market Size (USD million)	CAGR (Estimated)
2023	250	4-6%
2024	265
2025	280
2026	295
2027	310

3.4 Influencing Factors for Financial Trajectory

• Generic Competition: Dominance reduces prices but sustains volume.
• Emerging Indications & Formulations: New patents or delivery systems could extend revenue streams.
• Healthcare Policies: Increased focus on affordable treatments in lower-income countries.

---

4. Competitive Landscape

4.1 Key Players

Manufacturer	Market Share	Product Portfolio	Notable Developments
Teva Pharmaceuticals	40%	Generic acetazolamide products	Focus on biosimilars and formulations
Novartis	20%	Diamox (brand), generics	Market leadership in some regions
Mylan (now part of Viatris)	15%	Over-the-counter and prescription forms	Diversified product range
Others	25%	Multiple regional and local manufacturers	Niche formulations and combinations

4.2 Entry Barriers

• Regulatory Approvals: Difficult for new entrants without approved formulations.
• Manufacturing Complexity: Maintaining high-quality standards.
• Patent and Market Recognition: Older patents can limit innovation pathways.

---

5. Emerging Trends and Future Outlook

5.1 Technological and Formulation Innovations

• Sustained-release formulations could improve patient compliance.
• Combination therapies with other glaucoma agents or diuretics.
• Topical formulations are under development to reduce systemic side effects.

5.2 Policy and Market Opportunities

• Governments prioritizing affordable medications: open markets for generics.
• Digital health integration: monitoring compliance and efficacy.
• Expanding indications: potential use in novel neurological or metabolic conditions.

---

6. Comparison: Acetazolamide Sodium vs. Alternatives

Parameter	Acetazolamide Sodium	Alternatives	Differentiators
Therapeutic Scope	Glaucoma, altitude sickness, epilepsy	Brinzolamide, dorzolamide, topiramate	Cost, route of administration, efficacy
Patent Status	Expired, generics dominant	Varies, some patented	Patent life, formulations
Side Effects	Paresthesias, metabolic acidosis	Similar; some newer drugs have fewer adverse effects	Safety profile
Formulations	Oral, IV, compounded topicals	Oral, topical, injectables	Delivery options

---

7. FAQs

1. What factors most influence the pharmaceutical market for acetazolamide sodium?

Primarily, patent expirations, the prevalence of target diseases, competition from generics, and emerging formulations influence its market dynamics.

2. How does patent expiry impact sales projections?

Patent expiry leads to increased generic competition, lowering prices and profit margins but expanding accessible treatment options, maintaining overall market volume.

3. Are there new indications that could expand the use of acetazolamide sodium?

Research explores its potential in conditions like idiopathic intracranial hypertension and certain neurological disorders, though regulatory approvals are pending.

4. How does regional variation affect global sales?

Developed regions maintain stable demand due to aging populations, whereas emerging markets offer growth opportunities driven by increasing healthcare access.

5. What are the future growth prospects for acetazolamide sodium?

The global market is expected to grow at 4-6% CAGR over the next five years, driven by demand in glaucoma, altitude sickness, and potential new formulations.

---

Key Takeaways

• The acetazolamide sodium market is mature but sustained by the prevalence of glaucoma and altitude sickness.
• Patent expirations triggered a shift towards generics, capping branded revenue but expanding access.
• Emerging formulations and indications represent opportunities to extend product lifecycle and revenue.
• Competition from newer agents and regulatory landscapes will influence pricing and market share.
• Asia-Pacific represents significant growth potential, supported by demographic shifts and healthcare infrastructure expansion.

---

References

[1] WHO. "Global Burden of Glaucoma." World Health Organization, 2020.
[2] IMS Health Data. "Pharmaceutical Sales Analytics," 2022.
[3] U.S. FDA. "Drug Approvals and Indications," 2022.
[4] Market Research Future. "Pharmaceutical Market Analysis: 2023-2028," 2023.
[5] European Medicines Agency. "Review of Carbonic Anhydrase Inhibitors," 2021.